Weekly insights + SMS alerts
Charles River Laboratories International Inc. (NYSE:CRL) on Monday agreed to acquire the bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations of Frontage Holdings Corporation in Exton, Pennsylvania, for approximately $470 million in cash.
The transaction also includes up to $75 million in performance-based earnout payments, positioning Charles River to capture expanding biopharmaceutical demand.
The targeted assets encompass two testing facilities covering roughly 150,000 square feet and employing around 340 professionals.
These sites provide bioanalysis, biomarker, and DMPK testing across large and small molecules, anchored by a central laboratory that primarily supports clinical-stage biopharmaceutical clients.
Through this transaction, Charles River aims to balance its laboratory testing portfolio.
While preclinical programs for biologics and advanced modalities currently generate about 75% of Charles River's bioanalysis revenue, clinical-stage testing accounts for only 15%.
In contrast, Frontage generated the majority of its 2025 bioanalysis revenue during clinical development.
Market projections indicate the global bioanalysis sector will expand from approximately $6 billion in 2026 to between $8 billion and $9 billion by 2031, reflecting annual growth of 6% to 8%.
Charles River expects the newly acquired operations to match this trajectory over the next five years, driven by growing client demand for complex modalities and integrated pipeline data.
The purchase also bolsters Charles River's small molecule testing capabilities while unlocking operational synergies across its Discovery and Safety Assessment (DSA) and Manufacturing Solutions divisions.
The acquired operations generated roughly 40% of Frontage's $256.7 million total revenue in 2025. Charles River will integrate and report the business under its DSA segment.
Management anticipates the transaction will remain neutral to non-GAAP earnings per share in 2027 before turning accretive in subsequent years. Charles River plans to finance the acquisition through its credit facility and cash on hand. Both parties expect the deal to close during the first half of 2027.
William Blair on Monday wrote, "We view the acquisition as an attractive strategic addition that accelerates Charles River's efforts to build out its bioanalysis capabilities and expand its presence further into clinical development."
Analyst Jared Haase wrote that the transaction is directly in line with messaging at the company's recent investor day, where management highlighted bioanalysis as a strategic growth priority and outlined plans to expand clinical capabilities through organic investment and potential opportunistic M&A activity.
CRL Price Action: Charles River shares were down 2.51% at $344.47 at the time of publication on Tuesday, according to market data.
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
